U.S. District Court Orders 340B Report to Destroy and Not Divulge Legally Obtained Information in 340B Patient Definition Case

Screenshot of District of South Carolina Genesis Health Care Inc. v. Becerra et al court order
A federal district court ordered 340B Report to destroy and not divulge the contents of legally obtained records filed by the federal government in a lawsuit over the 340B patient definition.

A federal district court in South Carolina ordered 340B Report late yesterday to destroy and not release information from more than 9,000 pages of documents that the federal government filed in a public database Thursday in a community health center’s

Read More »

Congressional Committee Lineups Still in Flux After McCarthy Installed as House Speaker

House Speaker Kevin McCarthy in the speaker's chair
U.S. Rep. Kevin McCarthy (R-Calif.) takes the podium Jan. 7 after being elected as House Speaker.

The members, GOP chairs, and top-ranking Democrats of U.S. House committees for the 118th Congress still had not been formally announced this morning, three days after Republicans chose Rep. Kevin McCarthy (R-Calif.) to be House speaker.

It took four days

Read More »

340B “Overdue for Reform,” Industry Trade Group BIO Says in Blog

Screenshot of bionews.com 340B drug discount program story
The 340B program “is buckling under its own weight and overdue for reform,” BIO says in its blog.

The 340B program “is buckling under its own weight and overdue for reform,” biotechnology industry trade group BIO said last week in its blog.

BIO, which is marking its 30th anniversary in 2023, has experienced inner turmoil in recent

Read More »

CMS Plans in April to Address Potential Remedies for Illegal Drug Payment Cuts for 340B Hospitals

Screenshot of CMS meeting agenda
CMS plans to issue a proposed rule in April regarding “potential remedies” for illegal Part B drug payment cuts for 340B hospitals from 2018 through late September 2022.

Federal Medicare officials plan to issue a proposed rule in April regarding “potential remedies” for illegal Part B drug payment cuts for 340B hospitals from 2018 through late September 2022.

The Centers for Medicare & Medicaid Services revealed April as

Read More »

340B Provider Ally Stabenow Will Not Seek Re-Election to U.S. Senate in 2024

Sen. Debbie Stabenow (D-MI) headshot
U.S. Sen. Debbie Stabenow (D-Mich.) will not seek re-election in 2024, depriving 340B covered entities of a reliable ally.

U.S. Sen. Debbie Stabenow (D-Mich.) will not seek re-election in 2024, a decision that will deprive 340B covered entities of a reliable ally in Congress.

Stabenow issued a statement yesterday announcing her decision. She was one of six senators—three

Read More »

340B Pricing: Navigating Pharmacy Discount Programs to Benefit Your Entity & Patients

Jim Donnelly, Hudson Headwaters 340B

SPONSORED CONTENT

The 340B statute was written as a drug pricing program that outlines specifically what manufacturers are required to charge qualified covered entities for their drugs based on a defined formula. The intent of the 340B program is to help

Read More »

Janssen Providing Refunds for 340B Overcharges During Q1 2020

Janssen building signage
Janssen Pharmaceuticals is providing refunds to 340B covered entities for overcharges on 14 NDCs during Q1 2020.

Johnson & Johnson’s Janssen Pharmaceuticals division is providing refunds to 340B covered entities for overcharges on 14 NDCs during Q1 2020.

The U.S. Health Resources and Services Administration (HRSA) posted J&J’s refund notice yesterday. The company said the 340B

Read More »

340B INDUSTRY LEADER SPOTLIGHT

William von Oehsen, Principal, Powers Law Firm

William "Bill" von Oehsen, Principal, Powers Law Firm featured image
William "Bill" von Oehsen, Principal, Powers Law Firm
William von Oehsen

Q: Where did you grow up?

Central New Jersey

Q: Where did you go to college/graduate school?

Princeton (AB), Harvard (MTS), Georgetown (JD)

Q: What are

Read More »

Lilly Says 340B Entities Can’t Designate Central Fill Pharmacies as Contract Pharmacies

Lilly wordmark on top of building
Lilly updated its restrictions on 340B pricing to disallow covered entities from designating central fill pharmacies as contract pharmacies.

Drug manufacturer Eli Lilly late last month again updated its conditions on 340B pricing when covered entities use contract pharmacies.

Lilly was the first company to impose such conditions, starting with one drug in July 2020 then expanding to

Read More »

PhRMA Takes its Fight Against Arkansas 340B Law to Federal Appeals Court

U.S. Eighth Circuit Court of Appeals building
PhRMA has asked the federal appeals court in St. Louis to overturn a lower court's ruling that federal law does not preempt Arkansas’s novel 340B anti-discrimination law.

Brand drug manufacturers have asked a federal appeals court to overturn a judge’s ruling last month that Arkansas’s novel 340B anti-discrimination law is not preempted by the 340B statute nor by the U.S. Food and Drug Administration’s Risk Evaluation and

Read More »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
×

*Sign up for news summaries and alerts from 340B Report

Site Footer Live